ISG15-Mediated Suppression of Type I Interferon Signaling Leads to Susceptibility to Epstein-Barr Virus Infection (LCL_IFN_treatment_BulkRNAseq)
RNA-seq (gene expression) · human · 18 samples
- What it is
- RNA-seq (gene expression)Gene activity measured by sequencing. The summary does not mention single-cell work, so this is most likely bulk: one average per sample, the usual starting point for comparing groups.
- Organism
- Homo sapiens (human)
- Samples
- 18 samples: 18 samples, each with a distinct title — no replicated groupsGroups are read from the sample names, not from the paper. Check the list below.
- Data you can get
- A processed table (series matrix) and supplementary files from NCBI; the raw sequencing reads from ENA. Which of these hold counts depends on the study, so check the file list.
Read the full summary ↓
Direct links to NCBI and ENA, no account and no request form. Pick by what you want to do: take the small processed table to look, the supplementary files to re-analyse, or the original raw data to start over.
Processed table
The series matrix: one table of values per sample as the submitters processed it. The smallest download, and it opens in Excel or R. Start here to see what the data look like.
Supplementary files
The count tables and other files the authors uploaded. Take only the samples you need, or the whole study as GSE298341_RAW.tar (it can run to tens of gigabytes).
Raw sequencing reads
The original FASTQ files, straight from the sequencer, held at ENA. Large, and you align them yourself, so only choose this if you need to re-process the study from scratch.
What the files usually look like: For RNA-seq the counts are usually a table among the supplementary files (look for 'counts', 'expression', 'FPKM' or 'TPM' in the file name). The series matrix of a sequencing study is sometimes nearly empty.
Also filed as BioProject PRJNA1268989 and SRA study SRP588260. Searching any of these in the dataset finder brings you back here.
Any grouping that defines a comparison lives in the sample characteristics, which GEO records separately from the titles.
How we read this: Read from 18 sample titles: 18 distinct titles with little repetition. These groups are guessed from the sample names, not taken from the paper, so check them against the sample list below before relying on them.
- GSM9012168 EBV-LCLs, CD46 KO, untreated (biol rep 1)
- GSM9012169 EBV-LCLs, CD46 KO, IFN-treated (biol rep 1)
- GSM9012170 EBV-LCLs, CD46 KO, untreated (biol rep 2)
- GSM9012171 EBV-LCLs, CD46 KO, IFN-treated (biol rep 2)
- GSM9012172 EBV-LCLs, CD46 KO, untreated (biol rep 3)
- GSM9012173 EBV-LCLs, CD46 KO, IFN-treated (biol rep 3)
- GSM9012174 EBV-LCLs, ISG15 KO, untreated (biol rep 1)
- GSM9012175 EBV-LCLs, ISG15 KO, IFN-treated (biol rep 1)
- GSM9012176 EBV-LCLs, ISG15 KO, untreated (biol rep 2)
- GSM9012177 EBV-LCLs, ISG15 KO, IFN-treated (biol rep 2)
- GSM9012178 EBV-LCLs, ISG15 KO, untreated (biol rep 3)
- GSM9012179 EBV-LCLs, ISG15 KO, IFN-treated (biol rep 3)
- GSM9012180 EBV-LCLs, UBA7 KO, untreated (biol rep 1)
- GSM9012181 EBV-LCLs, UBA7 KO, IFN-treated (biol rep 1)
- GSM9012182 EBV-LCLs, UBA7 KO, untreated (biol rep 2)
- GSM9012183 EBV-LCLs, UBA7 KO, IFN-treated (biol rep 2)
- GSM9012184 EBV-LCLs, UBA7 KO, untreated (biol rep 3)
- GSM9012185 EBV-LCLs, UBA7 KO, IFN-treated (biol rep 3)
- GSE255658 Effects of lipopolysaccharide (LPS) or interferon gamma (IFNy) treatment on wild type or PILRA knock-out iPSC-derived human microglia after 24 hours 30 samples shares ifn, interferon
- GSE237879 IFN-III primes pDCs for TLR7 activation and antagonizes TGF-β mediated-immune suppression in tumors. 28 samples shares ifn, suppression
- GSE290417 Bulk RNA-sequencing of human Crohn's disease (CD) enteroids treated with interferon-gamma (IFNγ) 20 samples shares ifn, interferon
- GSE314089 Uncoupling the two distinct roles of targeting BDCA2 in treating autoimmune diseases: direct inhibition of BDCA2-positive B cells and normalization of proinflammatory monocyte-derived macrophages via the global suppression of type I IFN 16 samples shares ifn, suppression
- GSE282985 Schlafen 5 (SLFN5) is an Intracellular Immune Checkpoint and controls Interferon (IFN) Responses in Pancreatic Ductal Adenocarcinoma (PDAC) 14 samples shares ifn, interferon
- GSE290418 Bulk RNA-sequencing of human non-IBD enteroids treated with interferon-gamma (IFNγ) 12 samples shares ifn, interferon
- GSE277050 Loss of ARID1A leads to a cold tumor phenotype via suppression of IFNγ signaling 12 samples shares ifn, suppression
- GSE252917 Interferon subverts an AHR-JUN axis to promote CXCL13+ T cells in lupus [JUN IFN] 12 samples shares ifn, interferon
Metadata from NCBI GEO, cached and refreshed periodically — the NCBI page above is authoritative. Downloads link straight to NCBI/ENA; nothing is proxied through BioTransfer.